Articles published by Confo Therapeutics

Confo Therapeutics Announces Publication in Nature Communications Demonstrating First-Ever Structure of a Complex Between an Antibody-based Agonist and a Class A GPCR Regulating Hunger and Satiety

October 01, 2024

From Confo Therapeutics

Via Business Wire

Confo Therapeutics Announces EUR 60M Series B Financing to Advance Pipeline of Novel GPCR-Modulating Therapies into Clinical Development

July 26, 2024

From Confo Therapeutics

Via Business Wire

Confo Therapeutics Secures VLAIO Grant Supporting Drug Discovery & Development in Endocrine and Metabolic Diseases

March 28, 2024

From Confo Therapeutics

Via Business Wire

Confo Therapeutics Appoints Stephen Dowd as Chief Business Officer

September 12, 2023

From Confo Therapeutics

Via Business Wire

Confo Therapeutics Appoints Dieter Weinand, Former CEO of Bayer Pharmaceuticals, as Independent Chairman

August 29, 2023

From Confo Therapeutics

Via Business Wire

Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera

June 15, 2023

From Confo Therapeutics

Via Business Wire

Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases

March 30, 2023

From Confo Therapeutics

Via Business Wire

Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain Candidate, CFTX-1554

March 02, 2023

From Confo Therapeutics

Via Business Wire

Confo Therapeutics’ Scientific Founder Jan Steyaert Receives Prestigious Gabbay Award for Contributions to Structural Biology

October 28, 2022

From Confo Therapeutics

Via Business Wire

Confo Therapeutics Announces Poster Presentations on CFTX-1554 Preclinical Profiling and Mechanism of Action at the IASP 2022 World Congress on Pain

September 15, 2022

From Confo Therapeutics

Via Business Wire

Confo Therapeutics Awarded EUR 1.7M VLAIO Grant to Expand Application of ConfoBody® Drug Discovery and Development Technology in Rare Diseases

June 28, 2022

From Confo Therapeutics

Via Business Wire

Confo Therapeutics Expands Patent Estate for ConfoBody®-based GPCR Screening Platform

December 15, 2021

From Confo Therapeutics

Via Business Wire

Confo Therapeutics Enters Collaborative Agreement with Regeneron

November 30, 2021

From Confo Therapeutics

Via Business Wire

Confo Therapeutics Establishes Medical Advisory Board

June 10, 2021

From Confo Therapeutics

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.